Cargando…

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tiantian, Shi, Jing, Liu, Huasheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423312/
https://www.ncbi.nlm.nih.gov/pubmed/30693373
http://dx.doi.org/10.1007/s00277-018-03592-9
_version_ 1783404512385433600
author Ma, Tiantian
Shi, Jing
Liu, Huasheng
author_facet Ma, Tiantian
Shi, Jing
Liu, Huasheng
author_sort Ma, Tiantian
collection PubMed
description Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. We should make every effort to do further study about this immunotherapy to make it safer and effective. This review focusing on this topic clarifies the following contents: present status of MM treatment, effectiveness of CAR-T cells, features of BCMA, preclinical and clinical trials of BCMA CAR-T cells therapy, and existing problems and strategies. Hoping to provide a reference for the subsequent correlative clinical and research.
format Online
Article
Text
id pubmed-6423312
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64233122019-04-05 Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma Ma, Tiantian Shi, Jing Liu, Huasheng Ann Hematol Review Article Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. We should make every effort to do further study about this immunotherapy to make it safer and effective. This review focusing on this topic clarifies the following contents: present status of MM treatment, effectiveness of CAR-T cells, features of BCMA, preclinical and clinical trials of BCMA CAR-T cells therapy, and existing problems and strategies. Hoping to provide a reference for the subsequent correlative clinical and research. Springer Berlin Heidelberg 2019-01-28 2019 /pmc/articles/PMC6423312/ /pubmed/30693373 http://dx.doi.org/10.1007/s00277-018-03592-9 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Ma, Tiantian
Shi, Jing
Liu, Huasheng
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title_full Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title_fullStr Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title_full_unstemmed Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title_short Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
title_sort chimeric antigen receptor t cell targeting b cell maturation antigen immunotherapy is promising for multiple myeloma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423312/
https://www.ncbi.nlm.nih.gov/pubmed/30693373
http://dx.doi.org/10.1007/s00277-018-03592-9
work_keys_str_mv AT matiantian chimericantigenreceptortcelltargetingbcellmaturationantigenimmunotherapyispromisingformultiplemyeloma
AT shijing chimericantigenreceptortcelltargetingbcellmaturationantigenimmunotherapyispromisingformultiplemyeloma
AT liuhuasheng chimericantigenreceptortcelltargetingbcellmaturationantigenimmunotherapyispromisingformultiplemyeloma